Matinas BioPharma (MTNB) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 09, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38022
Entity Registrant Name	MATINAS BIOPHARMA HOLDINGS, INC.
Entity Central Index Key	0001582554
Entity Tax Identification Number	46-3011414
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1545 Route 206 South
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	908
Local Phone Number	484-8805
Title of 12(b) Security	Common Stock
Trading Symbol	MTNB
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		216,864,526

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 19,328,135	$ 21,029,806
Marketable securities	24,541,834	28,592,049
Restricted cash – security deposit	50,000	50,000
Prepaid expenses and other current assets	1,199,111	1,321,466
Total current assets	45,119,080	50,993,321
Non-current assets:
Leasehold improvements and equipment - net	2,013,322	1,537,728
Operating lease right-of-use assets - net	4,082,763	4,218,890
Finance lease right-of-use assets - net	15,835	22,270
In-process research and development	3,017,377	3,017,377
Goodwill	1,336,488	1,336,488
Restricted cash - security deposit	200,000	200,000
Total non-current assets	10,665,785	10,332,753
Total assets	55,784,865	61,326,074
Current liabilities:
Accounts payable	1,351,905	938,270
Accrued expenses	1,840,748	2,850,888
Operating lease liabilities - current	558,702	538,546
Financing lease liabilities - current	17,134	21,039
Total current liabilities	3,768,489	4,348,743
Non-current liabilities:
Deferred tax liability	341,265	341,265
Operating lease liabilities - net of current portion	3,993,396	4,140,387
Financing lease liabilities - net of current portion		2,621
Total non-current liabilities	4,334,661	4,484,273
Total liabilities	8,103,150	8,833,016
Stockholders’ equity:
Common stock par value $0.0001 per share, 500,000,000 shares authorized at March 31, 2022 and December 31, 2021; 216,864,526 and 216,269,450 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	21,685	21,627
Additional paid-in capital	185,901,685	184,251,138
Accumulated deficit	(137,612,481)	(131,634,208)
Accumulated other comprehensive loss	(629,174)	(145,499)
Total stockholders’ equity	47,681,715	52,493,058
Total liabilities and stockholders’ equity	$ 55,784,865	$ 61,326,074

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	0.0001	0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	216,864,526	216,269,450
Common stock, shares outstanding	216,864,526	216,269,450

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Research and development		$ 33,333
Costs and Expenses:
Research and development	4,978,105	3,241,432
General and administrative	2,744,195	3,145,010
Total costs and expenses	7,722,300	6,386,442
Loss from operations	(7,722,300)	(6,353,109)
Sale of New Jersey net operating loss & tax credits	1,734,133	1,328,470
Other income, net	9,894	68,319
Net loss	(5,978,273)	(4,956,320)
Preferred stock series B accumulated dividends		(210,900)
Net loss attributable to common shareholders	$ (5,978,273)	$ (5,167,220)
Net loss attributable to common shareholders per share - basic and diluted	$ (0.03)	$ (0.03)
Weighted average common shares outstanding:
Basic and diluted	216,644,783	203,871,820
Other comprehensive loss, net of tax
Unrealized loss on securities available-for-sale	$ (483,675)	$ (91,766)
Other comprehensive loss, net of tax	(483,675)	(91,766)
Comprehensive loss attributable to shareholders	$ (6,461,948)	$ (5,048,086)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Redeemable Convertible Preferred Stock B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 3,797,705	$ 20,010	$ 167,192,003	$ (107,507,193)	$ 228,172	$ 63,730,697
Beginning balance, shares at Dec. 31, 2020	4,361	200,113,431
Stock-based compensation			1,073,057			1,073,057
Issuance of common stock in exchange for Options		$ 85	1,211,942			1,212,027
Issuance of common stock in exchange for Options, shares		852,777
Other comprehensive loss					(91,766)	(91,766)
Net loss				(4,986,320)		(4,956,320)
Issuance of common stock as compensation for services		$ 1	7,937			7,938
Issuance of common stock as compensation for services, shares		7,560
Issuance of common stock in exchange for preferred stock	$ (124,529)	$ 29	124,500
Issuance of common stock in exchange for preferred stock, shares	(143)	286,000
Issuance of common stock in public offering, net of stock issuance costs ($172,592)		$ 302	5,580,169			5,580,471
Issuance of common stock in public offering, net of stock issuance costs, shares		3,023,147
Issuance of common stock from the exercise of Warrants
Issuance of common stock from the exercise of Warrants, shares		1,057
Ending balance, value at Mar. 31, 2021	$ 3,673,176	$ 20,427	175,789,608	(112,463,513)	136,406	66,556,104
Ending balance, shares at Mar. 31, 2021	4,218	204,283,972
Beginning balance, value at Dec. 31, 2021		$ 21,627	184,251,138	(131,634,208)	(145,499)	52,493,058
Beginning balance, shares at Dec. 31, 2021		216,269,450
Stock-based compensation			1,259,964			1,259,964
Issuance of common stock in exchange for Options		$ 18	99,423			99,441
Issuance of common stock in exchange for Options, shares		195,076
Issuance of common stock pursuant to license agreement amendment		$ 40	291,160			291,200
Issuance of common stock pursuant to license agreement amendment, shares		400,000
Other comprehensive loss					(483,675)	(483,675)
Net loss				(5,978,273)		(5,978,273)
Ending balance, value at Mar. 31, 2022		$ 21,685	$ 185,901,685	$ (137,612,481)	$ (629,174)	$ 47,681,715
Ending balance, shares at Mar. 31, 2022		216,864,526

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2021USD ($)
Common Stock [Member]
Payments of Stock Issuance Costs	$ 172,592

Condensed Consolidated Stateme

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (5,978,273)	$ (4,956,320)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	68,965	58,647
Stock based compensation expense	1,259,964	1,101,214
Amortization of operating lease right-of-use assets	136,127	126,896
Amortization of finance lease right-of-use assets	6,435	12,014
Amortization of bond discount	60,892	54,251
Stock issued pursuant to license agreement amendment	291,200
Changes in operating assets and liabilities:
Operating lease liabilities	(126,835)	(116,281)
Prepaid expenses and other current assets	122,355	386,346
Accounts payable	413,635	71,704
Accrued expenses and other liabilities	(1,010,140)	(1,389,584)
Net cash used in operating activities	(4,755,675)	(4,651,113)
Cash flows from investing activities:
Purchase of marketable securities	(2,494,352)	(4,083,141)
Proceeds from sales of marketable securities	6,000,000	12,900,000
Purchases of leasehold improvements and equipment	(544,559)
Net cash provided by investing activities	2,961,089	8,816,859
Cash flows from financing activities:
Net proceeds from public offering of common stock		5,580,472
Proceeds from exercise of options	99,441	1,212,027
Payments of capital lease liability - principal	(6,526)	(7,983)
Net cash provided by financing activities	92,915	6,784,516
Net (decrease)/increase in cash, cash equivalents and restricted cash	(1,701,671)	10,950,262
Cash, cash equivalents and restricted cash at beginning of period	21,279,806	12,768,481
Cash, cash equivalents and restricted cash at end of period	19,578,135	23,718,743
Supplemental non-cash financing and investing activities:
Unrealized loss on securities for sale	(483,675)	(91,766)
Preferred stock conversion into common stock - Series B		124,529
Unearned restricted stock grants		$ 48,301

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

Liquidity and Plan of Operation

Liquidity and Plan of Operations	3 Months Ended
	Mar. 31, 2022
Liquidity And Plan Of Operations
Liquidity and Plan of Operations	Note 2 – Liquidity and Plan of Operations The Company has experienced net losses and negative cash flows from operations each period since its inception. Through March 31, 2022, the Company had an accumulated deficit of approximately $ 137.6 6.0 5.0 The Company has been engaged in developing LYPDISO (formerly MAT9001) as well as its lipid nanocrystal (“LNC”) platform delivery technology and a pipeline of associated product candidates, including MAT2203 and MAT2501, since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales, and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. If the Company obtains Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing. As of March 31, 2022, the Company had cash and cash equivalents of approximately $ 19.3 24.5 0.3

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s 2021 Form 10-K. The Company’s management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company’s financial statements. COVID-19 Since its emergence in 2019, COVID-19 has continued to spread and has adversely affected workforces, economies, and financial markets globally, and has and may continue to cause economic downturns. The financial results for the three months ended March 31, 2022 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, and any further government and/or public actions taken in response to COVID-19.

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Marketable Securities	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Marketable Securities	Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Securities The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable securities. Cash and cash equivalents consisted of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. Cash, Cash Equivalents and Restricted Cash The Company presents restricted cash with cash and cash equivalents in the Condensed Consolidated Statements of Cash Flows. Restricted cash at both March 31, 2022 and December 31, 2021 of approximately $ 250 The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of March 31, 2022, December 31, 2021, March 31, 2021 and December 31, 2020: Schedule of Cash, Cash Equivalents and Restricted Cash March 31, December 31, March 31, December 31, Cash and cash equivalents $ 19,328 $ 21,030 $ 23,383 $ 12,432 Restricted cash included in current/long term assets 250 250 336 336 Cash, cash equivalents and restricted cash in the statement of cash flows $ 19,578 $ 21,280 $ 23,719 $ 12,768 Marketable Securities The Company has classified its investments in marketable securities as available-for-sale and as a current asset. The Company’s investments in marketable securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized losses and gains are classified as other comprehensive (loss)/income and costs are determined on a specific identification basis. Realized gains and losses from our marketable securities are recorded in other income, net. For the three months ended March 31, 2022 and 2021, the Company recorded unrealized losses of approximately $ 484 92 629 145 The following tables summarizes the Company’s marketable securities as of March 31, 2022: Summary of Marketable Securities Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 988 $ — $ (13 ) $ 975 U.S. Government Notes 18,378 — (519 ) 17,859 Corporate Debt Securities 5,555 — (97 ) 5,458 State and Municipal Bonds 250 — — 250 Total marketable securities $ 25,171 $ — $ (629 ) $ 24,542 Maturities of debt securities classified as available-for-sale were as follows at March 31, 2022: Schedule of Maturities of Debt Securities Available-for-sale Net Carrying Fair Value Amount Due within one year $ 5,253 $ 5,260 Due after one year through five years 19,289 19,349 $ 24,542 $ 24,609 The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following: Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value U.S. Government Notes $ 19,395 $ 2 $ (120 ) $ 19,277 Corporate Debt Securities 9,092 — (27 ) 9,065 State and Municipal Bonds 250 — — 250 Total marketable securities $ 28,737 $ 2 $ (147 ) $ 28,592 Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021: Fair Value Net Carrying Amount Due within one year $ 8,257 $ 8,310 Due after one year through five years 20,335 20,402 $ 28,592 $ 28,712

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5 - Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of cash equivalents, current portion of restricted cash, marketable securities, prepaid expenses and other current assets, accounts payable, current portion of lease liabilities and accrued expenses approximate fair value due to the short-term nature of these instruments. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities March 31, 2022 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy March 31, 2022 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 975 $ 975 $ — $ — U.S. Government Notes 17,859 — 17,859 — Corporate Debt Securities 5,458 — 5,458 — State and Municipal Bonds 250 — 250 — Total $ 24,542 $ 975 $ 23,567 $ — March 31, 2022 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy December 31, 2021 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Government Notes $ 19,277 $ — $ 19,277 $ — Corporate Debt Securities 9,065 — 9,065 — State and Municipal Bonds 250 — 250 — Total $ 28,592 $ — $ 28,592 $ — Marketable Securities $ 28,592 $ — $ 28,592 $ — U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable securities consisting of U.S. government notes, corporate debt securities and state and municipal bonds are classified as Level 2 and are valued using quoted market prices in markets that are not active.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment	Note 6 – Leasehold Improvements and Equipment Leasehold improvements and equipment, summarized by major category, consist of the following as of March 31, 2022 and December 31, 2021: Schedule of Leasehold Improvements and Equipment March 31, 2022 December 31, 2021 Equipment $ 1,964 $ 1,640 Leasehold improvements 1,155 935 Total 3,119 2,575 Less: accumulated depreciation and amortization 1,106 1,037 Leasehold improvements and equipment, net $ 2,013 $ 1,538 Depreciation and amortization expense for the three months ended March 31, 2022 and 2021 was approximately $ 69 59 220 324

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	Note 7 – Accrued Expenses and Other Liabilities Accrued Expenses, summarized by major category, as of March 31, 2022 and December 31, 2021 consist of the following: Schedule of Accrued Expenses March 31, 2022 December 31, 2021 Payroll and incentives $ 482 $ 1,343 General and administrative expenses 302 195 Research and development expenses 355 381 Deferred revenue and other deferred liabilities * 702 932 Total $ 1,841 $ 2,851 * At March 31, 2022, approximately $ 669 33 899 33

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases
Leases	Note 8 – Leases The Company has various lease agreements , including leases of office space, a laboratory and manufacturing facility, and various equipment. Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 Operating lease obligations The Company incurred lease expense for its operating leases of approximately $ 226 203 136 127 Finance Leases The Company incurred interest expense on its finance leases of approximately $ 1 6 12 The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of March 31, 2022: Schedule of Maturity of Operating and Finance Leases Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2022 $ 666 $ 15 2023 922 2 2024 962 - 2025 1,004 - 2026 1,046 - 2026 1,046 - Thereafter 1,112 - Total undiscounted operating lease payments $ 5,712 $ 17 Less: Imputed interest 1,160 - Present value of operating lease liabilities $ 4,552 $ 17 Weighted average remaining lease term in years 5.8 1.1 Weighted average discount rate 7.8 % 7.6 % The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021: Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2022 $ 883 $ 22 2023 922 2 2024 962 - 2025 1,004 - 2026 1,046 - Thereafter 1,112 - Total undiscounted operating lease payments $ 5,929 $ 24 Less: Imputed interest 1,250 - Present value of operating lease liabilities $ 4,679 $ 24 Weighted average remaining lease term in years 6.1 0.9 Weighted average discount rate 7.8 % 7.8 %

Collaboration Agreements, Licen

Collaboration Agreements, Licenses and Other Research and Development Agreements	3 Months Ended
	Mar. 31, 2022
Research and Development [Abstract]
Collaboration Agreements, Licenses and Other Research and Development Agreements	Note 9 - Collaboration Agreements, Licenses and Other Research and Development Agreements Cystic Fibrosis Foundation Therapeutics Development Award On November 19, 2020, the Company entered into an award agreement (the “CFF Agreement”) with the Cystic Fibrosis Foundation (“CFF”), pursuant to which it received a Therapeutics Development Award of up to $ 4.2 484 321 As of March 31, 2022, the Company has received $ 3.6 4.5 669 899 Genentech Feasibility Study Agreement On December 12, 2019, the Company entered into a feasibility study agreement (the “Genentech Agreement”) with Genentech, Inc. (“Genentech”). The Genentech Agreement involves the development of oral formulations using the Company’s LNC platform delivery technology. Under the terms of the Genentech Agreement, Genentech paid the Company a total of $ 100 33

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 10 – Income Taxes Sale of net operating losses (NOLs) & tax credits The Company recognized approximately $ 1.7 1.3

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders’ Equity	Note 11 – Stockholders’ Equity Common Stock On February 8, 2022, the Company issued 400,000 100,000 50,000 291 400,000 0.728 For the three months ended March 31, 2021, the Company sold 3,023,147 1.90 5.8 5.6 Warrants All warrants issued by the Company are exercisable immediately upon issuance and have a five-year term. The warrants may be exercised at any time in whole or in part upon payment of the applicable exercise price until expiration. No fractional shares will be issued upon the exercise of the warrants. The exercise price and the number of shares purchasable upon the exercise of the warrants are subject to adjustment upon the occurrence of certain events, which include stock dividends, stock splits, combinations and reclassifications of the Company’s capital stock or other similar changes to the equity structure of the Company. The warrants do not have a redemption feature. They may be exercised on a cashless basis at the holder’s option. The warrants are classified as equity instruments. As of March 31, 2022, the Company had outstanding warrants to purchase an aggregate of 988,000 0.50 0.75 Summary of Shareholders Equity Warrants Outstanding Shares Outstanding at December 31, 2020 1,328 Issued - Exercised (320 ) Tendered - Expired (20 ) Outstanding at December 31, 2021 988 Issued - Exercised - Tendered - Expired - Outstanding at March 31, 2022 988 * * Weighted average exercise price for outstanding warrants is $ 0.56 Basic and diluted net loss per common share During the three months ended March 31, 2022 and 2021, diluted earnings per common share is the same as basic earnings per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options, warrants and conversion of preferred stock, would have an anti-dilutive effect. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive as of March 31, 2022 and 2021: Schedule of Anti - Diluted Securities Excluded from Computation of Earning Per Share As of March 31, 2022 2021 Stock options 27,748 22,890 Warrants 988 1,326 Preferred Stock and accrued dividend as converted - 10,123 Total 28,736 34,339 Anti dilutive securities 28,736 34,339

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss)/Income	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Accumulated Other Comprehensive (Loss)/Income	Note 12 – Accumulated Other Comprehensive (Loss)/Income The following table summarizes the changes in accumulated other comprehensive income by components during the three months ended March 31, 2022 and 2021: Schedule of Components of Accumulated Other Comprehensive (Loss)/Income Net Unrealized (Losses)/Gains on Available-for-Sale Securities Accumulated Other Comprehensive Balance, December 31, 2021 $ (145 ) $ (145 ) Net unrealized loss on securities available-for-sale (484 ) (484 ) Net current period other comprehensive loss (484 ) (484 ) Balance, March 31, 2022 $ (629 ) $ (629 ) Balance, December 31, 2020 $ 228 $ 228 Net unrealized loss on securities available-for-sale (92 ) (92 ) Net current period other comprehensive income (92 ) (92 ) Balance, March 31, 2021 $ 136 $ 136 All components of accumulated other comprehensive income are net of tax.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 13 – Stock-based Compensation The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”) provides for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. There were no significant modifications to the Plan during the three months ended March 31, 2022 and 2021. The following table contains information about the Company’s stock plan at March 31, 2022: Schedule of Equity Compensation Plan by Arrangements Awards Awards Awards 2013 Equity Compensation Plan 45,603 * 32,429 ** 13,174 * Increased by 8,651 4 ** Includes both restricted stock grants and option grants The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended March 31, 2022 2021 Research and Development $ 550 $ 485 General and Administrative 710 616 Total $ 1,260 $ 1,101 As of March 31, 2022, total compensation costs related to unvested awards not yet recognized was approximately $ 10.5 2.7 Stock Options The following table summarizes the activity for Company’ stock options for the three months ended March 31, 2022: Schedule of Stock Option Activity Stock Options Outstanding at December 31, 2021 28,184 Granted 225 Exercised (195) Forfeited (100) Cancelled - Expired (366) Outstanding at March 31, 2022 27,748 Restricted Stock Awards During the three months ended March 31, 2022 and 2021, the Company granted restricted stock awards for 0 and 8 thousand shares of common stock, respectively. These awards are typically granted to members of the Board of Directors as payment in lieu of cash fees or as payment to a vendor pursuant to a consulting agreement. The Company values restricted stock awards at the fair market value on the date of grant. The Company recorded the value of these restricted awards as general and administrative expense of approximately $ 0 and $ 20 thousand in the condensed consolidated statement of operations for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, there was no unrecognized compensation costs related to restricted stock grants.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 14 – Commitments and Contingencies On March 7, 2022, the Company entered into an agreement with Thermo Fisher Scientific to provide scale-up and commercial manufacturing capabilities for MAT2203. The estimated fees under the agreement, including capital equipment requirements, are approximately $ 7.7 million. The fees are expected to be incurred over a two-year period beginning in March 2022 through the first quarter of 2024 .

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Event	Note 15 – Subsequent Event On April 8, 2022, the Company entered into an exclusive research collaboration with BioNTech SE to evaluate the combination of mRNA formats utilizing the Company’s proprietary LNC platform technology. Under the terms of the agreement, the Company will receive an exclusivity fee in the amount of $ 2.75 million, and BioNTech SE will fund certain of the Company’s research expenses related to the collaboration. The parties have also commenced discussions on a potential license agreement for the Company’s LNC platform technology.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s 2021 Form 10-K. The Company’s management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company’s financial statements.
COVID-19	COVID-19 Since its emergence in 2019, COVID-19 has continued to spread and has adversely affected workforces, economies, and financial markets globally, and has and may continue to cause economic downturns. The financial results for the three months ended March 31, 2022 were not significantly impacted by COVID-19. However, the Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, and any further government and/or public actions taken in response to COVID-19.

Cash, Cash Equivalents, Restr_2

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of March 31, 2022, December 31, 2021, March 31, 2021 and December 31, 2020: Schedule of Cash, Cash Equivalents and Restricted Cash March 31, December 31, March 31, December 31, Cash and cash equivalents $ 19,328 $ 21,030 $ 23,383 $ 12,432 Restricted cash included in current/long term assets 250 250 336 336 Cash, cash equivalents and restricted cash in the statement of cash flows $ 19,578 $ 21,280 $ 23,719 $ 12,768
Summary of Marketable Securities	The following tables summarizes the Company’s marketable securities as of March 31, 2022: Summary of Marketable Securities Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 988 $ — $ (13 ) $ 975 U.S. Government Notes 18,378 — (519 ) 17,859 Corporate Debt Securities 5,555 — (97 ) 5,458 State and Municipal Bonds 250 — — 250 Total marketable securities $ 25,171 $ — $ (629 ) $ 24,542 The following tables summarizes the Company’s marketable securities for the year ended December 31, 2021 consisted of the following: Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value Amortized Cost Unrealized Gain Unrealized (Loss) Fair Value U.S. Government Notes $ 19,395 $ 2 $ (120 ) $ 19,277 Corporate Debt Securities 9,092 — (27 ) 9,065 State and Municipal Bonds 250 — — 250 Total marketable securities $ 28,737 $ 2 $ (147 ) $ 28,592
Schedule of Maturities of Debt Securities Available-for-sale	Maturities of debt securities classified as available-for-sale were as follows at March 31, 2022: Schedule of Maturities of Debt Securities Available-for-sale Net Carrying Fair Value Amount Due within one year $ 5,253 $ 5,260 Due after one year through five years 19,289 19,349 $ 24,542 $ 24,609 Maturities of debt securities classified as available-for-sale were as follows at December 31, 2021: Fair Value Net Carrying Amount Due within one year $ 8,257 $ 8,310 Due after one year through five years 20,335 20,402 $ 28,592 $ 28,712

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurement of Assets and Liabilities	A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities March 31, 2022 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy March 31, 2022 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Treasury Bonds $ 975 $ 975 $ — $ — U.S. Government Notes 17,859 — 17,859 — Corporate Debt Securities 5,458 — 5,458 — State and Municipal Bonds 250 — 250 — Total $ 24,542 $ 975 $ 23,567 $ — March 31, 2022 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy December 31, 2021 Total (Level 1) (Level 2) (Level 3) Assets Marketable Securities: U.S. Government Notes $ 19,277 $ — $ 19,277 $ — Corporate Debt Securities 9,065 — 9,065 — State and Municipal Bonds 250 — 250 — Total $ 28,592 $ — $ 28,592 $ — Marketable Securities $ 28,592 $ — $ 28,592 $ —

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Leasehold Improvements and Equipment	Leasehold improvements and equipment, summarized by major category, consist of the following as of March 31, 2022 and December 31, 2021: Schedule of Leasehold Improvements and Equipment March 31, 2022 December 31, 2021 Equipment $ 1,964 $ 1,640 Leasehold improvements 1,155 935 Total 3,119 2,575 Less: accumulated depreciation and amortization 1,106 1,037 Leasehold improvements and equipment, net $ 2,013 $ 1,538

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued Expenses, summarized by major category, as of March 31, 2022 and December 31, 2021 consist of the following: Schedule of Accrued Expenses March 31, 2022 December 31, 2021 Payroll and incentives $ 482 $ 1,343 General and administrative expenses 302 195 Research and development expenses 355 381 Deferred revenue and other deferred liabilities * 702 932 Total $ 1,841 $ 2,851 * At March 31, 2022, approximately $ 669 33 899 33

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
Schedule of Maturity of Operating and Finance Leases Liabilities	The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of March 31, 2022: Schedule of Maturity of Operating and Finance Leases Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2022 $ 666 $ 15 2023 922 2 2024 962 - 2025 1,004 - 2026 1,046 - 2026 1,046 - Thereafter 1,112 - Total undiscounted operating lease payments $ 5,712 $ 17 Less: Imputed interest 1,160 - Present value of operating lease liabilities $ 4,552 $ 17 Weighted average remaining lease term in years 5.8 1.1 Weighted average discount rate 7.8 % 7.6 % The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2021: Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2022 $ 883 $ 22 2023 922 2 2024 962 - 2025 1,004 - 2026 1,046 - Thereafter 1,112 - Total undiscounted operating lease payments $ 5,929 $ 24 Less: Imputed interest 1,250 - Present value of operating lease liabilities $ 4,679 $ 24 Weighted average remaining lease term in years 6.1 0.9 Weighted average discount rate 7.8 % 7.8 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Summary of Shareholders Equity Warrants Outstanding	Summary of Shareholders Equity Warrants Outstanding Shares Outstanding at December 31, 2020 1,328 Issued - Exercised (320 ) Tendered - Expired (20 ) Outstanding at December 31, 2021 988 Issued - Exercised - Tendered - Expired - Outstanding at March 31, 2022 988 * * Weighted average exercise price for outstanding warrants is $ 0.56
Schedule of Anti - Diluted Securities Excluded from Computation of Earning Per Share	Schedule of Anti - Diluted Securities Excluded from Computation of Earning Per Share As of March 31, 2022 2021 Stock options 27,748 22,890 Warrants 988 1,326 Preferred Stock and accrued dividend as converted - 10,123 Total 28,736 34,339 Anti dilutive securities 28,736 34,339

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive (Loss)/Income (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Components of Accumulated Other Comprehensive (Loss)/Income	The following table summarizes the changes in accumulated other comprehensive income by components during the three months ended March 31, 2022 and 2021: Schedule of Components of Accumulated Other Comprehensive (Loss)/Income Net Unrealized (Losses)/Gains on Available-for-Sale Securities Accumulated Other Comprehensive Balance, December 31, 2021 $ (145 ) $ (145 ) Net unrealized loss on securities available-for-sale (484 ) (484 ) Net current period other comprehensive loss (484 ) (484 ) Balance, March 31, 2022 $ (629 ) $ (629 ) Balance, December 31, 2020 $ 228 $ 228 Net unrealized loss on securities available-for-sale (92 ) (92 ) Net current period other comprehensive income (92 ) (92 ) Balance, March 31, 2021 $ 136 $ 136

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Equity Compensation Plan by Arrangements	The following table contains information about the Company’s stock plan at March 31, 2022: Schedule of Equity Compensation Plan by Arrangements Awards Awards Awards 2013 Equity Compensation Plan 45,603 * 32,429 ** 13,174 * Increased by 8,651 4 ** Includes both restricted stock grants and option grants
Schedule of Recognized Stock-Based Compensation	The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended March 31, 2022 2021 Research and Development $ 550 $ 485 General and Administrative 710 616 Total $ 1,260 $ 1,101
Schedule of Stock Option Activity	The following table summarizes the activity for Company’ stock options for the three months ended March 31, 2022: Schedule of Stock Option Activity Stock Options Outstanding at December 31, 2021 28,184 Granted 225 Exercised (195) Forfeited (100) Cancelled - Expired (366) Outstanding at March 31, 2022 27,748

Liquidity and Plan of Operati_2

Liquidity and Plan of Operations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Liquidity And Plan Of Operations
Accumulated deficit	$ 137,612,481		$ 131,634,208
Net loss	6,000,000	$ 5,000,000
Cash and cash equivalents	19,328,135	$ 23,383,000	21,029,806	$ 12,432,000
Marketable securities	24,541,834		$ 28,592,049
Restricted cash	$ 300,000

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 19,328,135	$ 21,029,806	$ 23,383,000	$ 12,432,000
Restricted cash included in current/long term assets	250,000	250,000	336,000	336,000
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 19,578,000	$ 21,280,000	$ 23,719,000	$ 12,768,000

Summary of Marketable Securitie

Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost	$ 25,171	$ 28,737
Unrealized Gain		2
Fair Value	24,542	28,592
Unrealized (Loss)	(629)	(147)
US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost	988	19,395
Unrealized Gain		2
Fair Value	975	19,277
Unrealized (Loss)	(13)	(120)
US Government Agencies Debt Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost	18,378
Unrealized Gain
Fair Value	17,859
Unrealized (Loss)	(519)
Corporate Debt Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost	5,555	9,092
Unrealized Gain
Fair Value	5,458	9,065
Unrealized (Loss)	(97)	(27)
US States and Political Subdivisions Debt Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost	250	250
Unrealized Gain
Fair Value	250	250
Unrealized (Loss)

Schedule of Maturities of Debt

Schedule of Maturities of Debt Securities Available-for-sale (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Due within one year, fair value	$ 5,253	$ 8,257
Due within one year, net carrying amount	5,260	8,310
Due after one year through five years, fair value	19,289	20,335
Due after one year through five years, net carrying amount	19,349	20,402
Debt Securities Available-for-sale, fair value	24,542	28,592
Debt Securities Available-for-sale, net carrying amount	$ 24,609	$ 28,712

Cash, Cash Equivalents, Restr_3

Cash, Cash Equivalents, Restricted Cash and Marketable Securities (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash cash equivalents and restricted cash		$ 250	$ 250
Marketable securities, unrealized loss	$ 484	$ 92
Net accumulated unrealized losses	$ 629		$ 145

Schedule of Fair Value Measurem

Schedule of Fair Value Measurement of Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	$ 24,542	$ 28,592
Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	975
Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	23,567	28,592
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
US Treasury Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	975
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	975
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
US Government Agencies Debt Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	17,859	19,277
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	17,859	19,277
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Corporate Debt Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	5,458	9,065
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	5,458	9,065
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
US States and Political Subdivisions Debt Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	250	250
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities	250	250
US States and Political Subdivisions Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable Securities

Schedule of Leasehold Improveme

Schedule of Leasehold Improvements and Equipment (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total	$ 3,119,000	$ 2,575,000
Less: accumulated depreciation and amortization	1,106,000	1,037,000
Leasehold improvements and equipment, net	2,013,322	1,537,728
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	1,964,000	1,640,000
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,155,000	$ 935,000

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation and amortization expenses	$ 69,000	$ 59,000
Purchase of equipment and leasehold improvements	544,559
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Purchase of equipment and leasehold improvements	220,000
Equipment [Member]
Property, Plant and Equipment [Line Items]
Purchase of equipment and leasehold improvements	$ 324,000

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)		Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll and incentives		$ 482,000	$ 1,343,000
General and administrative expenses		302,000	195,000
Research and development expenses		355,000	381,000
Deferred revenue and other deferred liabilities	[1]	702,000	932,000
Total		$ 1,840,748	$ 2,850,888
[1]	At March 31, 2022, approximately $ 669 33 899 33

Schedule of Accrued Expenses _2

Schedule of Accrued Expenses (Details) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CFF Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred liability	$ 669	$ 899
Genentech Feasibility Study Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue	$ 33	$ 33

Schedule of Maturity of Operati

Schedule of Maturity of Operating and Finance Leases Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases
Operating lease liabilities, Remainder of fiscal year	$ 666
Finance Lease Liabilities, Remainder of fiscal year	15
Operating Lease Liabilities, Year one	922	$ 883
Finance Lease Liabilities, Year one	2	22
Operating Lease Liabilities, Year two	962	922
Finance Lease Liabilities, Year two		2
Operating Lease Liabilities, Year three	1,004	962
Finance Lease Liabilities, Year three
Operating Lease Liabilities, Year four	1,046	1,004
Finance Lease Liabilities, Year four
Operating lease Liabilities, Year five		1,046
Finance Lease Liabilities, Year five
Operating Lease Liabilities, Thereafter	1,112	1,112
Finance Lease Liabilities, Thereafter
Total undiscounted operating lease payments	5,712	5,929
Total undiscounted finance lease payments	17	24
Operating Lease Liabilities, less: Imputed interest	1,160	1,250
Finance Lease Liabilities, less: Imputed interest
Present value of operating lease liabilities	4,552	4,679
Present value of finance lease liabilities	$ 17	$ 24
Operating Lease Liabilities, weighted average remaining lease term in years	5 years 9 months 18 days	6 years 1 month 6 days
Finance Lease Liabilities, weighted average remaining lease term in years	1 year 1 month 6 days	10 months 24 days
Operating Lease Liabilities, weighted average discount rate	7.80%	7.80%
Finance Lease Liabilities, weighted average discount rate	7.60%	7.80%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases
Operating lease, description	Some leases include purchase, termination or extension options for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised
Remaining lease term	12 months
Lease expense	$ 226,000	$ 203,000
Operating lease right-of-use assets amortization expenses	136,127	126,896
Finance lease, interest expense	1,000	1,000
Finance lease right-of-use assets amortization expenses	$ 6,435	$ 12,014

Collaboration Agreements, Lic_2

Collaboration Agreements, Licenses and Other Research and Development Agreements (Details Narrative) - USD ($)	Nov. 19, 2021	Nov. 19, 2020	Dec. 12, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue					$ 33,333
Award Agreement [Member] | Cystic Fibrosis Foundation [Member]
Therapeutics development award		$ 4,200,000
Proceeds from award		$ 484,000
Additional milestone payment	$ 321,000
CFF Agreement [Member]
Grants Receivable				3,600,000
Additional milestone payment				4,500,000
CFF Agreement [Member] | Accrued Expense and Other Current Liabilities [Member]
Other Liabilities				$ 669,000		$ 899,000
Genentech Feasibility Study Agreement [Member] | Genentech [Member]
Agreement description			Under the terms of the Genentech Agreement, Genentech paid the Company a total of $100 thousand for the development of three molecules, or approximately $33 thousand per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.
Deferred revenue			$ 100,000
Revenue			$ 33,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Sale of net operating losses	$ 1.7	$ 1.3

Summary of Shareholders Equity

Summary of Shareholders Equity Warrants Outstanding (Details) - shares shares in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022		Dec. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Shares Outstanding, beginning	988		1,328
Shares Issued
Shares Exercised			(320)
Shares Tendered
Shares Expired			(20)
Shares Tendered
Shares Outstanding, ending	988	[1]	988	1,328
[1]	Weighted average exercise price for outstanding warrants is $ 0.56

Summary of Shareholders Equit_2

Summary of Shareholders Equity Warrants Outstanding (Details) (Parenthetical)	Mar. 31, 2022$ / shares
Equity [Abstract]
Weighted average of exercise price for outstanding warrants	$ 0.56

Schedule of Anti - Diluted Secu

Schedule of Anti - Diluted Securities Excluded from Computation of Earning Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	28,736	34,339
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	27,748	22,890
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities	988	1,326
Preferred Stock and Accrued Dividend as Converted [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti dilutive securities		10,123

Schedule of Components of Accum

Schedule of Components of Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Equity [Abstract]
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Beginning Balance	$ (145,000)	$ 228,000
Accumulated Other Comprehensive (Loss)/Gain, Beginning Balance	(145,499)	228,000
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net unrealized gain (loss) on securities available-for-sale	(484,000)	(92,000)
Accumulated Other Comprehensive (Loss)/Gain, Net unrealized gain (loss) on securities available-for-sale	(484,000)	(92,000)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Net current period other comprehensive loss	(484,000)	(92,000)
Accumulated Other Comprehensive (Loss)/Gain, Net current period other comprehensive loss	(484,000)	(92,000)
Net Unrealized Gains (Losses) on Available-for-Sale Securities, Ending Balance	(629,000)	136,000
Accumulated Other Comprehensive (Loss)/Gain, Ending Balance	$ (629,000)	$ 136,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)	Feb. 08, 2022	Mar. 31, 2022	Mar. 31, 2021
Class of Stock [Line Items]
Research and development expense		$ 4,978,105	$ 3,241,432
Number of warrant to purchase of common stock		988,000
Maximum [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 0.50
Minimum [Member]
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 0.75
BTIGLLC [Member[
Class of Stock [Line Items]
Stock issued during new issued, shares			3,023,147
Average price, per share			$ 1.90
Gross proceeds from common stock			$ 5,800,000
Proceeds from common stock			$ 5,600,000
Restated Exclusive License Agreement [Member]
Class of Stock [Line Items]
Milestone fee	$ 100,000
License fee	50,000
Research and development expense	$ 291,000
Stock issued during new issued, shares	400,000
Share price	$ 0.728
Restated Exclusive License Agreement [Member] | Unregistered Shares [Member] | Rutgers [Member]
Class of Stock [Line Items]
Business acquisition, equity iterest issued or issuable, shares	400,000

Schedule of Equity Compensation

Schedule of Equity Compensation Plan by Arrangements (Details) - 2013 Equity Compensation Plan [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2022shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Awards Reserved for Issuance	45,603	[1]
Awards Issued & Exercised	32,429	[2]
Awards Available for Grant	13,174
[1]	Increased by 8,651 4
[2]	Includes both restricted stock grants and option grants

Schedule of Equity Compensati_2

Schedule of Equity Compensation Plan by Arrangements (Details) (Parenthetical) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2021	Jan. 02, 2022
Share-Based Payment Arrangement [Abstract]
Increased shares of common stock outstanding		8,651
Percentage for common stock outstanding	4.00%

Schedule of Recognized Stock-Ba

Schedule of Recognized Stock-Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 1,259,964	$ 1,101,214
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	550,000	485,000
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 710,000	$ 616,000

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2022shares
Share-Based Payment Arrangement [Abstract]
Number of Options, Outstanding at Beginning	28,184,000
Number of Options, Granted	225,000
Number of Options, Exercised	(195,000)
Number of Options, Forfeited	(100,000)
Number of Options, Cancelled
Number of Options, Expired	(366,000)
Number of Options, Outstanding at Ending	27,748,000

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Option Indexed to Issuer's Equity [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	0	8
Other General and Administrative Expense	$ 0	$ 20
Stock Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Unrecognized share based compensation	$ 10,500
Share based compensation weighted average period	2 years 8 months 12 days

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Commercial fees	$ 7.7
Other commitments, description	The fees are expected to be incurred over a two-year period beginning in March 2022 through the first quarter of 2024

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) $ in Thousands	Apr. 08, 2022USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Exclusivity fee	$ 2,750